Clinical trials, a type of research that studies the safety and efficacy of potential therapeutics in people, must be conducted before bringing new medicines to patients. The U.S. Food and Drug Administration (FDA) and other global healthcare regulatory agencies review data on investigational medicines before clinical trials may start. Clinical trials would not be possible without the collaboration of the people living with the cancers we aim to treat, healthcare professionals, and advocacy groups.

Clinical trials for adults with certain types of cancer are underway

TRIAL
Phase
Status
Indication
NCT ID
Regions
Sponsor
ASCEND logo
CR-001
Phase1/2
StatusRecruiting
IndicationNSCLC, other solid tumors
RegionsUS, Europe, S. Korea
SponsorCrescent Biopharma
CR-001 (SKB118)
Phase1/2
StatusRecruiting
IndicationNSCLC, other solid tumors
RegionsGreater China
SponsorKelun-Biotech
CR-001 (SKB118) in combination with
sac-TMT
Phase2
StatusRecruiting
IndicationNSCLC
RegionsGreater China
SponsorKelun-Biotech
CR-001 (SKB118) in combination with
sac-TMT
Phase2
StatusRecruiting
Indication2L nsq NSCLC
RegionsGreater China
SponsorKelun-Biotech
CR-001 (SKB118) in combination with
sac-TMT
Phase2
StatusRecruiting
IndicationSolid tumors
RegionsGreater China
SponsorKelun-Biotech
TRIAL
Phase
Status
Indication
NCT ID
Regions
Sponsor
APOLLO logo
CR-002
Phase1/2
StatusRecruiting
IndicationNSCLC, HNSCC, other solid tumors
RegionsUS, Europe, Asia Pacific (planned)
SponsorCrescent Biopharma
TRIAL
Phase
Status
Indication
NCT ID
Regions
Sponsor
CR-003 (SKB105)
Phase1/2
StatusRecruiting
IndicationSolid tumors
RegionsGreater China
SponsorKelun-Biotech

Clinical Trial FAQ

What is a clinical trial?
A clinical trial is a carefully designed research study that helps doctors learn whether a potential new medicine or treatment is safe and how well it works. Clinical trials are reviewed and monitored by experts to help protect participants.
Who can participate in a clinical trial?
Participation in a clinical trial is voluntary, but each study has specific eligibility criteria that participants must meet. The trial team at the site you choose will review your medical history and current health status to determine whether the study may be a good fit for you. You may also be asked to share information from your medical records to help the team assess your eligibility.
What is an investigational medicine?
An investigational medicine is a potential treatment that is being studied in clinical trials but has not yet been approved for use for a specific condition by the FDA or another healthcare regulatory agency. Clinical trials help researchers learn whether an investigational medicine is safe and how well it works for people with a specific disease or condition.
How do I decide if a clinical trial is right for me?
If you are eligible for a clinical trial and are interested in learning more, the study team will review the trial with you, including its purpose, required assessments and procedures, possible risks and potential benefits, and any precautions to consider. You will receive an informed consent form and have time to ask questions, and you may want to discuss the trial with your doctor, family, caregiver, or another trusted support person before deciding whether participation is right for you.
Is there a cost to participate?
Study participants receive the study medicine, as well as study-related visits, tests, and assessments, at no cost. Some study-related expenses, such as travel costs, may also be reimbursed.
Who do I contact if I have more questions?
If you have any questions about participating in a Crescent-sponsored clinical trial, email clinicaltrials@crescentbiopharma.com.
Smiling older man talking with his doctor in an exam room

Expanded access policy

Crescent Biopharma, Inc. is a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients. We are committed to conducting clinical trials to evaluate the safety and efficacy of our investigational therapies. These trials are essential to obtaining the required marketing approvals that enable physicians to prescribe these therapies and support broad patient access.

In some circumstances, a treating physician may make a request to provide an unapproved therapy to a qualifying individual, which must be approved by the U.S. Food and Drug Administration (FDA) and supported by the pharmaceutical manufacturer. This is called an expanded access program (EAP), sometimes known as “compassionate use,” and refers to a potential pathway for a patient with a serious or life-threatening disease or condition to try an investigational therapy outside of a clinical trial when there is no comparable or satisfactory therapy available.

We currently have investigational therapies in our pipeline for the treatment of cancer. While we understand that some patients may wish to access our unapproved investigational therapies, our goal is to provide access to our therapies at the appropriate time and in a manner that is most beneficial to the relevant patient population. At this stage of our development, Crescent does not currently offer an expanded access program. We believe enrollment in our ongoing clinical trials is the safest and most effective way of obtaining access to Crescent’s investigational therapies and we encourage all patients and physicians who are interested in accessing our investigational therapies to visit the clinicaltrials.gov website to find out about enrolling.

Crescent may revise this expanded access policy at any time. Additionally, the posting of this policy by Crescent does not serve as a guarantee of access to any specific investigational new drug by any individual patient.

If you have any questions, please reach out to us at clinicaltrials@crescentbiopharma.com.